Dr. Binu Malhotra, MD

Dr. Malhotra practices at Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health.

Dr. Malhotra's NPI, 1104023118, was assigned on July 2, 2007. Dr. Malhotra holds Michigan license 4301097901.

Dr. Malhotra's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth, at 100 Michigan St NE, Grand Rapids, MI 49503 in Kent County. The practice phone is (616) 391-1774.

Dr. Malhotra's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health. Dr. Malhotra is also affiliated with Covenant Medical Center Harrison. The medical group on file is The Cancer & Hematology Centers. Dmand AI also links Dr. Malhotra to 3 more hospitals, 5 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Malhotra practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Malhotra's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Malhotra is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Malhotra's licenses on file in 2 states: Michigan and Indiana.

CMS data shows 654 Medicare services from Dr. Malhotra across 16 procedure codes in 2024, for 126 Medicare patients. Medicare paid $32,471 for them.

CMS counts 126 Medicare patients who saw Dr. Malhotra in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Malhotra's median patient age at 68, with 55% women.

In 2024, Dr. Malhotra wrote 950 Medicare Part D claims for 271 patients. 80% of them were for generic drugs. CMS names the drug for 724 of them, across 24 drugs with 11 or more claims each, at $1,194,541 in total drug cost. In 2023, CMS named 2,834 claims across 52 drugs.

Dr. Malhotra accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Malhotra as offering telehealth.

Dmand AI links 6 papers to Dr. Malhotra, published from 2011 to 2025. The most frequent topics are Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung and Pyrimidines. Dr. Malhotra's most frequent co-authors are Francis Paul Worden, MD, Zubair W. Baloch, MD and Joseph I. Clark, MD.

Dmand AI links Dr. Malhotra to 3 clinical trials, 2 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Colorectal Neoplasms, Hereditary Nonpolyposis and Rectal Diseases. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 267 general payments to Dr. Malhotra from 62 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 94% of the total. Janssen Pharmaceuticals, Inc paid the most, $426.